Sghealthcare KRX:398120KOSDAQ
에스지헬스케어 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days2
Articles tracked7since Sep 11
In Q2 2026, Sghealthcare reported revenue of ₩4.2bn, up 1.9% year on year, and an operating loss of ₩751m. Sghealthcare (에스지헬스케어) appeared in 0 Korean news articles and 2 DART filings over the past seven days.
Filing signals Supply contract Screener
Sghealthcare quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.2bn | +1.9% | −₩751m margin −17.9% | −₩668m |
| Q1 2026 | ₩4.9bn | +34.9% | ₩162m margin 3.3% | ₩24m |
| Q4 2025 derived | ₩11.7bn | +227.1% | ₩2.1bn margin 18.0% | ₩1.6bn |
| Q3 2025 | ₩5.1bn | +133.5% | ₩96m margin 1.9% | ₩66m |
| Q2 2025 | ₩4.1bn | -50.8% | −₩444m margin −10.8% | −₩366m |
| Q1 2025 | ₩3.7bn | +86.1% | −₩290m margin −7.9% | −₩403m |
| Q4 2024 derived | ₩3.6bn | – | −₩1.1bn margin −29.5% | −₩3.5bn |
| Q3 2024 | ₩2.2bn | – | −₩629m margin −28.7% | −₩1.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Sghealthcare top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Sghealthcare news Korean headlines
-
에스지헬스케어, 中 CASHIM '삼중입자 치료시스템' 국내 독점 사업권 확보
2 more on this story · 2 outlets
- 에스지헬스케어, 中 카심 삼중입자 치료시스템 국내 독점 사업권 확보이투데이 · Sep 29 09:21
- 에스지헬스케어, 中 카심 입자치료 시스템 국내 독점 사업권 확보컨슈머타임스 · Sep 29 09:45
-
멕아이씨에스, 9억9천만원 유상증자…에스지헬스케어에 제3자배정
1 more on this story · 1 outlets
- 멕아이씨에스, 9억9000만원 유상증자…에스지헬스케어에 제3자배정아시아경제 · Sep 14 17:48